Viernes, 21 Octubre 2016
Ultimas noticias
Casa » Pfizer Inc. (NYSE:PFE) Analyst Estimates And Rating

Pfizer Inc. (NYSE:PFE) Analyst Estimates And Rating

19 Octubre 2016

During the 52-week trading session the minimum price at which share price traded, registered at $11.65 and reached to max level of $41.97.The Earnings per Share of the company stands at $0.49.Fitbit (FIT), the leader in the connected health and fitness market, recently declared pre-sale global availability of the highly anticipated accessory collection created in partnershipwith NY design house PUBLIC SCHOOL for Fitbit Alta™.

Other Hedge Funds, Including, Cwm reduced its stake in PFE by selling 62,847 shares or 16.18% in the most recent quarter. Pfizer Inc. has a 52-week low of $28.25 and a 52-week high of $37.39. Analysts rating the company a 3 indicate a Hold recommendation. Ronna Sue Cohen now owns 7,881 shares of the biopharmaceutical company's stock valued at $277,000 after buying an additional 35 shares during the last quarter. 1 Month Ago, shares have been suggested as BUY from and issued SELL signal for the company's stock. told as a HOLD the stock.

Pfizer Inc. (NYSE:PFE) have shown a high EPS growth of 1.60% in the last 5 years and has earnings growth of -58.80% yoy. The average numbers of shares are traded in a security per day, during the recent 3-month period.

EPS in next five year years is expected to touch 6.05% while EPS growth in past 5 year was 1.60% along with sales growth of -5.60% in the last five years. Pfizer has a one year low of $28.25 and a one year high of $37.39. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the Zacks' consensus estimate of $0.62 by $0.02. The Return on Equity (ROE) value stands at 10.9%. The firm earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. The company's 5 year Earnings per share growth and Capital Spending growth remains at 1.59 and -0.23. The insider owns 2,134,851 shares which have current market value of around $69788279.19.William C. Steere, Jr is another major inside shareholder in the company.

Investors should note that on Sep 22, 2016, Pfizer announced a cash dividend of $0.3000. The tofacitinib presentations will highlight new research results from the Phase 3 Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) Induction trials, counting one oral presentation looking at the effect of prior treatment with tumor necrosis factor inhibitors (TNFi) on efficacy endpoints. The company's management has announced Nov 9, 2016 as the ex-dividend date and fixed the record date on Nov 11, 2016.

With that in mind, Pfizer Inc. (NYSE:PFE). These ratios are important while doing valuation of the company or the shares of the company. Delphi Private Advisors LLC raised its stake in shares of Pfizer by 1.2% in the second quarter. Monthly stock performance comes in at -2.85%. Pfizer makes up approx 0.99% of Genesee Valley Trust Co's portfolio.Raymond James Trust N.a. boosted its stake in PFE in the latest quarter, The investment management firm added 14,447 additional shares and now holds a total of 458,955 shares of Pfizer which is valued at $15,425,478. The insider owns 1,265,131 shares as of less than 0.1%, now worth $41357132.39. Finally, Murphy Pohlad Asset Management LLC increased its position in shares of Pfizer by 12.8% in the first quarter. New England Private Wealth Advisors LLC now owns 18,135 shares of the biopharmaceutical company's stock worth $639,000 after buying an additional 77 shares in the last quarter. He performs analysis of Healthcare Companies and provides worthy information for investor community.

Pfizer Inc is a research-based global biopharmaceutical company. The attained acreage complements, and is partially contiguous to, the Company's recently closed Howard County acreage acquisition and includes about 2,400 Boe per day net production. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products.